Idiopathic inflammatory myopathies
- PMID: 34857798
- DOI: 10.1038/s41572-021-00321-x
Idiopathic inflammatory myopathies
Abstract
Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune disorders with varying clinical manifestations, treatment responses and prognoses. Muscle weakness is usually the classical clinical manifestation but other organs can be affected, including the skin, joints, lungs, heart and gastrointestinal tract, and they can even result in the predominant manifestations, supporting that IIM are systemic inflammatory disorders. Different myositis-specific auto-antibodies have been identified and, on the basis of clinical, histopathological and serological features, IIM can be classified into several subgroups - dermatomyositis (including amyopathic dermatomyositis), antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myositis. The prognoses, treatment responses and organ manifestations vary among these groups, implicating different pathophysiological mechanisms in each subtype. A deeper understanding of the molecular pathways underlying the pathogenesis and identifying the auto-antigens of the immune reactions in these subgroups is crucial to improving outcomes. New, more homogeneous subgroups defined by auto-antibodies may help define disease mechanisms and will also be important in future clinical trials for the development of targeted therapies and in identifying biomarkers to guide treatment decisions for the individual patient.
© 2021. Springer Nature Limited.
Similar articles
-
Classification of idiopathic inflammatory myopathies: pathology perspectives.Curr Opin Neurol. 2019 Oct;32(5):704-714. doi: 10.1097/WCO.0000000000000740. Curr Opin Neurol. 2019. PMID: 31369423 Review.
-
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598. JAMA Neurol. 2018. PMID: 30208379 Free PMC article.
-
Idiopathic inflammatory myopathies.Neurol Clin. 2014 Aug;32(3):595-628, vii. doi: 10.1016/j.ncl.2014.04.007. Neurol Clin. 2014. PMID: 25037081 Free PMC article. Review.
-
Inflammatory muscle disease - An update.Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101484. doi: 10.1016/j.berh.2019.101484. Epub 2020 Feb 8. Best Pract Res Clin Rheumatol. 2020. PMID: 32046904 Review.
-
Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.Int J Mol Sci. 2022 Apr 13;23(8):4301. doi: 10.3390/ijms23084301. Int J Mol Sci. 2022. PMID: 35457124 Free PMC article. Review.
Cited by
-
Spirituality, Religiosity, and Mental Health in Patients with Idiopathic Inflammatory Myopathies: A Brazilian Multicentric Case-Control Study.Int J Environ Res Public Health. 2024 May 21;21(6):653. doi: 10.3390/ijerph21060653. Int J Environ Res Public Health. 2024. PMID: 38928900 Free PMC article.
-
Case report: Antisynthetase syndrome with positive anti-PL7/SSA/RO52 antibodies.Heliyon. 2024 Aug 24;10(17):e36880. doi: 10.1016/j.heliyon.2024.e36880. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39281462 Free PMC article.
-
Impaired muscle stem cell function and abnormal myogenesis in acquired myopathies.Biosci Rep. 2023 Jan 31;43(1):BSR20220284. doi: 10.1042/BSR20220284. Biosci Rep. 2023. PMID: 36538023 Free PMC article. Review.
-
A Narrative Review of Acthar Gel for the Treatment of Myositis.Rheumatol Ther. 2023 Jun;10(3):523-537. doi: 10.1007/s40744-023-00545-1. Epub 2023 Mar 26. Rheumatol Ther. 2023. PMID: 36966453 Free PMC article. Review.
-
Current Biomarker Strategies in Autoimmune Neuromuscular Diseases.Cells. 2023 Oct 15;12(20):2456. doi: 10.3390/cells12202456. Cells. 2023. PMID: 37887300 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical